Aptamer Group PLC Net Assets

Latest as of June 2025: GBX1.38 Million GBX ≈ $168.15 USD

Aptamer Group PLC net assets. Based on the latest financial reports, Aptamer Group PLC (APTA) has net assets worth GBX1.38 Million GBX (≈ $168.15 USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX2.83 Million ≈ $344.82 USD) and total liabilities (GBX1.45 Million ≈ $176.67 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Aptamer Group PLC to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX1.38 Million
% of Total Assets 48.76%
Annual Growth Rate 7.11%
5-Year Change 1216.19%
10-Year Change N/A
Growth Volatility 2820.39

Net Assets of Aptamer Group PLC (2019–2025)

Net assets of Aptamer Group PLC from 2019 to 2025. This chart illustrates how Aptamer Group PLC's net assets have evolved over time, based on quarterly financial data. See net asset quality index of Aptamer Group PLC to measure how much of total assets are equity-financed.

Annual Net Assets for Aptamer Group PLC (2019–2025)

The table below shows the annual net assets of Aptamer Group PLC from 2019 to 2025. For live market cap and overall valuation, see APTA stock market capitalisation.

Year Net Assets Change
2025-06-30 GBX1.38 Million
≈ $168.15
+55.81%
2024-06-30 GBX887.00K
≈ $107.92
+191.78%
2023-06-30 GBX304.00K
≈ $36.99
-96.22%
2022-06-30 GBX8.05 Million
≈ $979.57
+7567.62%
2021-06-30 GBX105.00K
≈ $12.78
-57.28%
2020-03-31 GBX245.81K
≈ $29.91
-72.68%
2019-03-31 GBX899.87K
≈ $109.49
--

Equity Component Analysis

This analysis shows how different components contribute to Aptamer Group PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 1245216100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Aptamer Group PLC Net Assets Breakdown (June 2025)

Aptamer Group PLC net assets breakdown by equity component as of June 2025.

Component Amount Percentage
Common Stock GBX1.99 Million 144.07%
Other Comprehensive Income GBX619.00K 44.79%
Other Components GBX13.63 Million 986.54%
Total Equity GBX1.38 Million 100.00%

Aptamer Group PLC Competitors by Market Cap

The table below lists competitors of Aptamer Group PLC ranked by their market capitalization.

Company Market Cap
ANGLE plc
LSE:AGL
$94.18K
Boostheat
PA:ALBOO
$94.37K
CAP-XX Limited
LSE:CPX
$94.84K
Green Leaf Innovations Inc.
NASDAQ:GRLFD
$95.41K
Ceps PLC
LSE:CEPS
$93.26K
Nexus Infrastructure plc
LSE:NEXS
$92.88K
Tap Global Group Plc
LSE:TAP
$92.86K
CORE ASSETS CORP.
F:5RJ
$92.51K

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Aptamer Group PLC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 887,000 to 1,382,000, a change of 495,000 (55.8%).
  • Net loss of 2,424,000 reduced equity.
  • New share issuances of 2,891,000 increased equity.
  • Other comprehensive income increased equity by 115,000.
  • Other factors decreased equity by 87,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income GBX-2.42 Million -175.4%
Share Issuances GBX2.89 Million +209.19%
Other Comprehensive Income GBX115.00K +8.32%
Other Changes GBX-87.00K -6.3%
Total Change GBX- 55.81%

Book Value vs Market Value Analysis

This analysis compares Aptamer Group PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 369.91x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 21.83x to 369.91x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2019-03-31 GBX0.01 GBX0.29 x
2020-03-31 GBX0.00 GBX0.29 x
2021-06-30 GBX0.00 GBX0.29 x
2022-06-30 GBX0.12 GBX0.29 x
2023-06-30 GBX0.00 GBX0.29 x
2024-06-30 GBX0.00 GBX0.29 x
2025-06-30 GBX0.00 GBX0.29 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Aptamer Group PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -175.40%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -201.50%
  • • Asset Turnover: 0.42x
  • • Equity Multiplier: 2.05x
  • Recent ROE (-175.40%) is above the historical average (-742.73%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2019 -50.56% -46.11% 0.71x 1.55x GBX-544.97K
2020 -274.50% -78.96% 0.61x 5.65x GBX-699.31K
2021 -1761.52% -144.50% 0.62x 19.66x GBX-1.86 Million
2022 -26.00% -51.86% 0.35x 1.43x GBX-2.90 Million
2023 -2577.63% -447.26% 0.64x 9.06x GBX-7.87 Million
2024 -333.48% -343.95% 0.31x 3.12x GBX-3.05 Million
2025 -175.40% -201.50% 0.42x 2.05x GBX-2.56 Million

Industry Comparison

This section compares Aptamer Group PLC's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $8,280,651
  • Average return on equity (ROE) among peers: -130.41%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Aptamer Group PLC (APTA) GBX1.38 Million -50.56% 1.05x $93.52K
4BASEBIO UK SOCIETAS (4BB) $11.70 Million -27.66% 0.26x $998.55K
Arecor Therapeutics PLC (AREC) $5.35 Million -191.36% 0.63x $356.03K
Avacta Group PLC (AVCT) $19.13 Million -52.99% 0.12x $2.86 Million
BSF Enterprise Plc (BSFA) $423.14K -22.20% 0.08x $15.62K
Bioventix (BVXP) $851.00K 0.00% 1.80x $1.24 Million
Cizzle Biotechnology Holdings PLC (CIZ) $2.40 Million -115.05% 1.12x $55.46K
CRISM Therapeutics Corporation (CRTX) $23.48 Million -13.39% 0.12x $81.89K
Fusion Antibodies PLC (FAB) $16.32K -695.70% 18.23x $72.60K
Faron Pharmaceuticals Oy (FARN) $11.18 Million -55.36% 0.33x $401.90K

About Aptamer Group PLC

LSE:APTA UK Biotechnology
Market Cap
$93.52K
GBX768.64 Million GBX
Market Cap Rank
#31546 Global
#1116 in UK
Share Price
GBX0.29
Change (1 day)
+0.00%
52-Week Range
GBX0.29 - GBX1.08
All Time High
GBX153.00
About

Aptamer Group PLC, together with its subsidiaries, provides synthetic binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally. The company offers Optimer, a platform that enables the discovery and development of optimized DNA and RNA aptamers, which can bind to target molecules. Its platform is used in research reagent and … Read more